Skip to main content
Journal of Patient-Reported Outcomes
Fig. 1 | Journal of Patient-Reported Outcomes

Fig. 1

From: Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

Fig. 1

Study design. aIn the ePRO cohort, other IO therapies indicated for the solid tumors of interest could be considered after launch of the study. bVoluntary enrollment in the ePRO platform within 45 days of index date. cUntil death, loss to follow-up, pregnancy, enrollment in a clinical trial, or 6 months post-IO therapy initiation. dDate on which the first cycle of IO therapy was initiated after diagnosis. ePRO electronic patient-reported outcome; HC historical control; IO immuno-oncology

Back to article page